It has also been seen that patients on insulin or insulin-secreting agents (e.g., sulphonylureas) are at a higher risk of developing cancer compared to patients on oral insulin-sensitizing agents, e.g., metformin or thiazolidinediones (TZDs). Here, INS is linked to cancer.